The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials

Int J Surg. 2023 Nov 1;109(11):3648-3655. doi: 10.1097/JS9.0000000000000656.

Abstract

Background: There is a debate over the use of aspirin after total knee arthroplasty (TKA) for venous thromboembolism (VTE) prophylaxis. To evaluate the clinical effectiveness and safety of aspirin after TKA, the authors performed a meta-analysis of randomized controlled trials that compared aspirin with low-molecular-weight heparin (LMWH).

Methods: PubMed, Cochrane Library, Embase, and Web of Science were last searched on 31 January 2023 for studies comparing the effect of VTE prophylaxis between aspirin and LMWH. The results of eligible studies were analyzed in terms of VTE, deep venous thrombosis, pulmonary embolism, and bleeding complications rates.

Results: Six randomized controlled trials including 6772 patients met the inclusion criteria. LMWH showed a statistically significant reduction in the overall VTE rate (RR 1.46, 95% CI: 1.16-1.84). No significant differences in deep venous thrombosis, pulmonary embolism, and bleeding complications rates were found between aspirin and LMWH.

Conclusion: Compared with LMWH, aspirin presents a higher risk of VTE after TKA. In terms of safety, aspirin and LMWH show comparable outcomes. The results do not support the role of aspirin role as an anticoagulant for preventing VTE after TKA.

Publication types

  • Meta-Analysis

MeSH terms

  • Anticoagulants / adverse effects
  • Arthroplasty, Replacement, Knee* / adverse effects
  • Aspirin / adverse effects
  • Heparin / therapeutic use
  • Heparin, Low-Molecular-Weight / adverse effects
  • Humans
  • Pulmonary Embolism* / complications
  • Pulmonary Embolism* / prevention & control
  • Randomized Controlled Trials as Topic
  • Venous Thromboembolism* / etiology
  • Venous Thromboembolism* / prevention & control
  • Venous Thrombosis* / etiology
  • Venous Thrombosis* / prevention & control

Substances

  • Heparin, Low-Molecular-Weight
  • Aspirin
  • Anticoagulants
  • Heparin